BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 7682358)

  • 1. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
    Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
    [No Abstract]   [Full Text] [Related]  

  • 2. FK 506 rescue therapy: early conversion improves efficacy.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
    [No Abstract]   [Full Text] [Related]  

  • 3. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
    [No Abstract]   [Full Text] [Related]  

  • 4. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach.
    Woodle ES; Perdrizet GA; So SK; White HM; Marsh JW
    Clin Transplant; 1995 Feb; 9(1):45-52. PubMed ID: 7537988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
    Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826
    [No Abstract]   [Full Text] [Related]  

  • 6. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
    Wiesner RH; Porayko MK; Wahlstrom HE; Gores GJ; Kamath PS; Hay JE; Krom RA
    Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
    [No Abstract]   [Full Text] [Related]  

  • 8. FK 506 treatment of intractable rejection after liver transplantation.
    Jost U; Winkler M; Ringe B; Rodeck B; Pichlmayr R
    Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
    [No Abstract]   [Full Text] [Related]  

  • 9. Rejection: FK 506 for rescue or maintenance.
    Klintmalm GB; Gibbs JF; McMillan R; Backman L; Levy M; Goldstein RM; Husberg BS; Holman MJ; Gonwa TA
    Transplant Proc; 1993 Apr; 25(2):1914-5. PubMed ID: 7682356
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rejection of a liver allograft. Diagnosis and treatment].
    Calmus Y
    Ann Radiol (Paris); 1994; 37(5):377-82. PubMed ID: 7527621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
    Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy.
    Scott-Douglas N; Zimmerman D; Klassen J
    Transplant Proc; 1996 Dec; 28(6):3165. PubMed ID: 8962226
    [No Abstract]   [Full Text] [Related]  

  • 13. Intensive care after orthotopic liver transplantation.
    Sun CK; Chen CL; Kuo YC; Chen YS
    Transplant Proc; 1994 Aug; 26(4):2246-7. PubMed ID: 7520627
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
    Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Wahlstrom HE; Sanchez-Urdazpal L; Richards T; Crotty P; Beaver S
    Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
    [No Abstract]   [Full Text] [Related]  

  • 16. FK 506 used as rescue therapy for refractory liver allograft rejection.
    Chen CL; Eng HL; Chen YS; Kuo YC; Sun CK
    Transplant Proc; 1994 Aug; 26(4):1927-9. PubMed ID: 7520612
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion to rescue therapy with FK 506: data from eight liver transplant patients.
    Reggiani P; Orsenigo R; Gatti S; Albani AP; Ferla G; Doglia M; Fassati LR; Galmarini D
    Transplant Proc; 1994 Dec; 26(6):3597-8. PubMed ID: 7527982
    [No Abstract]   [Full Text] [Related]  

  • 18. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection.
    Lewis WD; Jenkins RL; Burke PA; Winn KM; Shaffer D; Lopez R; Monaco AP
    Transplant Proc; 1991 Dec; 23(6):2989-91. PubMed ID: 1721336
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic findings after liver transplantation within a randomised trial with or without steroids.
    Tisone G; Angelico M; Vennarecci G; Palmieri G; Buonomo O; Negrini S; Casciani CU
    Transplant Proc; 1998 Jun; 30(4):1447-8. PubMed ID: 9636587
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of FK 506 for treatment of chronic rejection after liver transplantation.
    Winkler M; Ringe B; Gerstenkorn C; Rodeck B; Gubernatis G; Wonigeit K; Pichlmayr R
    Transplant Proc; 1991 Dec; 23(6):2984-6. PubMed ID: 1721334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.